CD274 and neoplasm: Excitedly, the FDA recently approved PD-1 inhibitor Pembrolizumab (Keytruda) combined chemotherapy (Albumin paclitaxel/paclitaxel with or without carboplatin) as a new adjuvant therapy for the unresectable or metastatic triple-negative breast cancer (TNBC) with PD-L1 expression in ≥10% tumor cells.